Status:

COMPLETED

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Lead Sponsor:

Melinta Therapeutics, Inc.

Conditions:

Community-Acquired Bacterial Pneumonia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in the treatment of adults with moderate to moderately severe community-acquired bacterial pneumonia.

Detailed Description

Community-acquired bacterial pneumonia is an acute infection of the pulmonary parenchyma with symptoms such as fever or hypothermia, chills, rigors, chest pain, and/or dyspnea. The widespread emergenc...

Eligibility Criteria

Inclusion

  • Diagnosis of community acquired bacterial pneumonia (e.g. cough with purulent sputum or change in character of sputum consistent with bacterial infection, dyspnea or tachypnea, chest pain due to pneumonia, fever, presence of rales and/or signs of consolidation).
  • No prior systemic antibacterial therapy, unless failed other therapy.
  • Chest Xray shows new lobar or multilobar infiltrate(s) consistent with acute bacterial pneumonia.
  • PORT Risk Class II, III, or IV \<=105
  • Ability to take oral medication.

Exclusion

  • Severe chronic obstructive pulmonary disease FEV1 \<30%.
  • Hospitalization within 90 days or residence in a long-term-care facility within 30 days prior to the onset of symptoms
  • Chemotherapy or radiation therapy within the previous 3 months.
  • Significant hepatic, hematological, renal abnormalities.
  • Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g. life expectancy \<30 days).

Key Trial Info

Start Date :

August 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

132 Patients enrolled

Trial Details

Trial ID

NCT01168713

Start Date

August 1 2010

End Date

July 1 2011

Last Update

March 3 2017

Active Locations (55)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (55 locations)

1

Birmingham, Alabama, United States, 35242

2

Flagstaff, Arizona, United States, 86001

3

Bell Gardens, California, United States, 90201

4

Chula Vista, California, United States, 91911